The Saudi Food and Drug Authority has granted marketing authorization to two locally developed AI-powered medical software products designed to support diagnosis in dentistry and ophthalmology, marking a significant step forward for the Kingdom’s digital health and medical technology ecosystem.
The two products are Dental IQ and SAARIA. Their authorization followed the completion of regulatory assessments that included reviews of technical documentation and clinical evidence to verify their safety, performance and effectiveness for their intended uses.
Dental IQ Supports Dental X-Ray Analysis
Dental IQ uses deep-learning algorithms to analyze dental X-ray images and support healthcare professionals in identifying potential pathological findings at an early stage.
The software is designed to assist in identifying indicators associated with dental caries, periodontal disease and structural changes affecting the teeth and supporting tissues.
By providing an AI-assisted analysis of dental images, the software is intended to support diagnostic accuracy and help practitioners develop appropriate treatment plans.
SAARIA Supports Early Detection of Diabetic Retinopathy
The second product, SAARIA, uses artificial intelligence to analyze retinal fundus images and support the screening of diabetic patients for early signs of diabetic retinopathy.
The system is designed to help identify patients who may require specialized ophthalmic assessment, potentially enabling faster referrals and earlier intervention to reduce the risk of complications associated with the disease.
A National Milestone for AI-Enabled Medical Software
The authorization represents an important milestone for Saudi Arabia’s digital health sector. According to the SFDA, the two products are the first Saudi-developed AI-enabled medical software solutions in dentistry and ophthalmology to receive marketing authorization from the authority.
Both solutions are intended as clinical support tools that assist healthcare professionals rather than replace professional medical judgment.
The products were developed by Saudi startups specializing in AI-driven digital health solutions. The companies joined the SFDA’s Innovative Medical Devices Pathway, receiving early regulatory guidance and support while completing the applicable requirements for market authorization.
Local Clinical Studies Strengthen Validation
The regulatory process went beyond technical assessments. The developers conducted clinical studies in Saudi Arabia to validate the performance of the software in local healthcare settings.
They also committed to post-marketing clinical follow-up plans designed to monitor real-world performance and ensure the continued safe use of the products after entering the market.
This approach highlights the growing importance of regulatory frameworks capable of keeping pace with rapidly evolving medical AI while maintaining requirements for clinical evidence, safety and effectiveness.
AI Enters a New Phase in Healthcare
The authorization of Saudi-developed AI medical software reflects the expanding role of artificial intelligence in healthcare, particularly in medical imaging, screening and early detection.
AI-based tools can provide healthcare professionals with additional capabilities for analyzing large volumes of medical images and identifying potential indicators that may require further assessment.
However, their effectiveness depends on being integrated into a broader clinical workflow in which AI outputs remain part of the diagnostic process rather than replacing professional evaluation.
AI Does Not Replace the Doctor
The SFDA stressed that outputs generated by AI-enabled medical software do not replace consultation with a qualified healthcare professional.
Healthcare professionals remain responsible for reviewing and validating the results, assessing each patient’s condition and making appropriate clinical decisions.
This principle is particularly important as healthcare systems worldwide increasingly adopt AI technologies, making responsible regulation and clinical oversight essential to ensuring that innovation translates into safe and reliable patient care.
Advancing the Localization of Medical Technology
The SFDA said the authorization is part of its broader efforts to support innovation in digital health, promote the development and localization of advanced medical technologies and facilitate market access for innovative healthcare solutions that meet safety, effectiveness and quality requirements.
The move also supports the objectives of Saudi Arabia’s Health Sector Transformation Program, one of the Vision 2030 programs, particularly in advancing innovation and the adoption of emerging technologies across healthcare.
With Dental IQ and SAARIA now authorized for marketing, Saudi Arabia is further developing a domestic digital-health ecosystem that brings together startups, artificial intelligence, clinical research and specialized regulation.
The milestone could also pave the way for additional Saudi-developed medical technologies to move from research and innovation into regulated healthcare applications, strengthening the Kingdom’s position in the rapidly expanding global digital health market.
